DrugGen 2: A disease-aware language model for enhancing drug discovery

2026-07-09 · Source: Machine Learning · Field: Science & Research — Life Sciences & Biology, Health & Medical Research, Artificial Intelligence & Machine Learning · Depth: Expert, quick

Summary

DrugGen-2 is a novel generative model designed to enhance drug discovery by conditioning small molecule generation on both disease ontology and target protein sequences. It addresses the common oversight in computational drug design of neglecting disease context. Developed by fine-tuning a pre-trained GPT-2 model, DrugGen-2 utilized a two-step strategy of supervised fine-tuning followed by reinforcement learning via group relative policy optimization (GRPO). This process was guided by reward functions optimizing for chemical validity, novelty, diversity, and high predicted binding affinity. Evaluated on five protein targets relevant to diabetic nephropathy, DrugGen-2 significantly outperformed baseline models like DrugGPT and DrugGen. It demonstrated superior generation of unique molecules, greater structural similarity to approved drugs, and improved predicted binding affinities across all targets. Molecular docking analyses identified candidate ligands with strong binding potential, including compounds with predicted affinities (-9.917, -9.485, and -9.367) exceeding reference drugs such as enalapril (-8.283).

Key takeaway

For AI Scientists and Machine Learning Engineers developing drug discovery platforms, DrugGen-2 demonstrates the critical value of integrating disease ontology with target protein sequences. You should consider incorporating disease-specific context into your generative models to improve molecular novelty, diversity, and predicted binding affinities. This approach can lead to identifying more potent candidate ligands and accelerate de novo drug design or repurposing efforts.

Key insights

DrugGen-2 integrates disease context and target sequences to generate novel small molecules with superior binding affinities.

Principles

• Disease context improves molecular generation.
• Reinforcement learning refines drug discovery models.
• Multi-objective reward functions guide molecular design.

Method

DrugGen-2 fine-tunes a pre-trained GPT-2 model using supervised fine-tuning, then reinforcement learning (GRPO) with rewards for validity, novelty, diversity, and binding affinity.

In practice

• Design de novo molecules considering disease context.
• Repurpose existing drugs for specific diseases.
• Identify candidate ligands with high binding potential.

Topics

• Drug Discovery
• Generative Models
• Disease Ontology
• GPT-2 Fine-tuning
• Reinforcement Learning
• Molecular Docking

Best for: AI Scientist, Machine Learning Engineer, Research Scientist

Related on AIssential

• DrugGen 2: A disease-aware language model for enhancing drug discovery — DrugGen-2 is a disease-aware generative AI model that significantly improves de novo drug design by integrating disease ontology.
• Bridging the phenotype-target gap for molecular generation via multi-objective reinforcement learning — ExMolRL combines phenotype-guided generation with target-aware reinforcement learning for de novo drug discovery.
• DualGPT-AB: a dual-stage generative optimization framework for therapeutic antibody design — DualGPT-AB optimizes therapeutic antibody design by combining conditional GPT with reinforcement learning for multi-property sequence generation.
• AI is reengineering drug discovery by speeding up testing and scanning petabytes of data for connections between diseases — AI significantly enhances drug discovery by analyzing vast data to predict targets, efficacy, and disease interrelationships, improving success rates.
• Generative Artificial Intelligence in Bioinformatics: A Systematic Review of Models, Applications, and Methodological Advances — Generative AI, particularly specialized models, is transforming bioinformatics by enabling de novo design and superior analytical performance.
• SPOKE: A massive biomedical knowledge graph for precision health and drug discovery — SPOKE integrates vast biomedical data into a knowledge graph for drug discovery and precision medicine.

See Counsel's argued verdicts on the open AI decisions leaders are weighing →

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Machine Learning.